[go: up one dir, main page]

WO2025109005A1 - Immunothérapie pour le traitement d'une allergie - Google Patents

Immunothérapie pour le traitement d'une allergie Download PDF

Info

Publication number
WO2025109005A1
WO2025109005A1 PCT/EP2024/082996 EP2024082996W WO2025109005A1 WO 2025109005 A1 WO2025109005 A1 WO 2025109005A1 EP 2024082996 W EP2024082996 W EP 2024082996W WO 2025109005 A1 WO2025109005 A1 WO 2025109005A1
Authority
WO
WIPO (PCT)
Prior art keywords
allergen
dose
compositions
composition
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/082996
Other languages
English (en)
Inventor
Vrede-Sherden TIMMINS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Allergy Ltd
Original Assignee
Cambridge Allergy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Allergy Ltd filed Critical Cambridge Allergy Ltd
Publication of WO2025109005A1 publication Critical patent/WO2025109005A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
    • A61J7/0418—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers with electronic history memory
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
    • A61J7/0481—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers working on a schedule basis
    • A61J7/049—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers working on a schedule basis automatically changing in response to a schedule deviation by the patient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0076—Medicament distribution means
    • A61J7/0084—Medicament distribution means for multiple medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
    • A61J7/0454—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers for dispensing of multiple drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Definitions

  • the present invention relates to methods and means of immunotherapy for the treatment of allergy, such as food allergy, and formulations and dosing devices for use in such methods.
  • Allergy is a prevalent and potentially life-threatening condition that negatively affects guality of life. Allergy affects nearly every body system, causing wide-ranging symptoms that are often persistent and severe. Allergy is caused by an over production of specific serum IgE by the immune system, directed against otherwise harmless proteins or complex molecules, leading to sensitisation of mast cells and eventual clinical allergic reactions on re-encountering the allergen.
  • Immunotherapy an established approach for treating allergies, modifies the immune system with repeated exposure to the allergen, inducing it to tolerate specific harmful allergens.
  • Immunotherapy uses pre-measured doses of the specific allergens that individual patients are reactive to, administered to patients by multiple alternative routes (e.g., oral, sublingual, injection, inhalation, or transcutaneously). Immunotherapy doses are administered freguently (e.g. daily). Immunotherapy regimens begin with a very small initial dose, before escalation to much larger maintenance doses (for example 100- fold or larger than the initial dose) over an ‘up-dosing phase’, which lasts several months, and is followed by continuation at the same ‘maintenance dose’. Extended periods of maintenance dosing cause desensitization to much larger amounts of the allergen.
  • dose escalation during the ‘up-dosing phase’ has been comprised of series of stepwise dose increments, with regimens designed with a small number of dose increments spread over several months.
  • This regimen design is based on i) practicalities of manufacture and supply of the treatment and ii) to ensure that patients are able to span the dose range from initiation dose to maintenance dose within a reasonable time frame. Together, these considerations have resulted in the oral immunotherapy dose regimes requiring the use of large, often 25-100% dose increases given in a single day, with each followed by a series of days of dosing at home at the same dose.
  • Palforzia There is one existing licensed immunotherapy for food allergy, Palforzia.
  • Palforzia is licensed for treatment of peanut allergy and is only licenced for children aged 4- 17 years of age. There are no licensed treatments for adults with peanut allergy.
  • Palforzia Over the past three years, Palforzia has seen limited adoption in both the UK and US.
  • Nestle which owned Palforzia, pinpointed the primary reason for its subdued reception in a November 2022 announcement: the treatment’s demanding updosing regimen had proved too taxing for both patients and physicians. This regimen mandates 12 clinic visits, over six months, with each visit requiring a long cool off period, which creates large staff and space requirements. Immunotherapy is provided in single dose units.
  • the present inventors have developed methods of immunotherapy that employ up-dosing schedules in which allergen is administered at regular time intervals and the dose of allergen is incrementally increased at each administration. This continuous up-dosing reduces adverse side-effects in patients compared to periodic up-dosing.
  • the present inventors have also developed dosing devices and allergen formulations that are advantageously suited for use in these methods.
  • a first aspect of the invention provides a method of immunotherapy comprising;
  • the regular time interval of dose administration in steps (a) and (b) is daily.
  • allergen is administered orally in methods of the first aspect.
  • a method of the first aspect may further comprise administering the initial dose of allergen to the individual at regular time intervals before step (a).
  • the allergen in methods of the first aspect is peanut protein.
  • a second aspect of the invention provides a set of compositions comprising a first allergen composition comprising 1 to 10% (w/w) allergen and a second allergen composition having 20 to 30% (w/w) allergen.
  • the first allergen composition comprises 5% (w/w) allergen.
  • the second allergen composition comprises 20% (w/w) allergen.
  • the allergen compositions in the set may be bulk formulations that are not separated into individual doses.
  • the formulations of the first and second allergen compositions allow for the use of allergen extracts that vary in allergen content.
  • a first allergen composition of the second aspect may have the formula
  • V 100 - (l+ll+lll+IV) % (w/w) mannitol granules wherein x is the % (w/w) allergen in the allergen extract.
  • a second allergen composition of the second aspect may have the formula
  • V 100 -(l+ll+lll+IV) % (w/w) mannitol granules wherein x is the % (w/w) allergen in the allergen extract.
  • the allergen extract is peanut flour.
  • the set of allergen compositions of the second aspect may be used in the methods of the first aspect.
  • a third aspect of the invention provides a dosing device for use in a method of immunotherapy comprising; a cartridge, wherein the cartridge contains a bulk formulation of allergen for administration, an actuator for dispensing a defined dose of allergen from the bulk formulation in the cartridge, and a control unit comprising a processor, wherein the processor is programmed to operate the actuator to dispense the define dose of allergen in accordance with a predetermined dose regimen.
  • the cartridge of the dosing device may contain a first and/or a second allergen composition of the set of compositions of the second aspect.
  • a dosing device of the third aspect may be useful in a method of the first aspect.
  • Figure 1 shows an embodiment of a dose metering and dispensing device, comprising a reusable control unit, disposable drug-containing cartridge, and detachable cup.
  • Figure 2 shows an example of protein profiles of drug substance batches.
  • Figure 3 shows the process of manufacture of the allergen compositions.
  • Figure 4 shows a granule manufacture flow chart.
  • Figure 5 shows a cartridge manufacture flow chart
  • Figure 6 shows an example continuous up-dosing regimen, approximately tracking the discrete up-dosing regimen.
  • This invention relates to methods of immunotherapy that comprise administering an allergen to an individual in need thereof in a series of administrations, in which the dose of allergen increases incrementally by 1% to 10% on each administration from an initial starting dose to a final maintenance dose.
  • the administrations may be at regular time intervals, preferably daily.
  • These methods of immunotherapy may be performed using a dosing device for metering and dispensing doses of allergen and/or formulations that allow the consistent dispensation of accurate doses of allergen in accordance with the method.
  • Immunotherapy induces down-regulation of mast cell and basophil effector cells in the individual leading to a state of desensitization to the allergen.
  • Immunotherapy using the methods described herein reduces or avoids adverse side-effects associated with up-dosing, such as anaphylaxis, thereby reducing or avoiding the need for frequent clinic visits and/or concomitant prophylactic therapies and enhancing the convenience and efficiency of immunotherapy.
  • the methods described herein allow the rate of increase of doses to be personalised to the patient. For example, if a patient experiences adverse effects from treatment, then a slower rate of increase may be employed.
  • Allergen may be administered orally or sub-lingually in the methods described herein.
  • the allergen is administered orally (i.e. oral immunotherapy).
  • An allergen is an antigen capable of inducing an allergic response in a mammalian subject, preferably a human subject.
  • Allergens may include food allergens and inhalant allergens.
  • the allergen may be a single allergen or a mixture of two or more allergens in powdered, granulated, or other suitable forms.
  • Allergens may include proteins, for example plant proteins, such as peanut protein, tree nut protein, soy protein, wheat protein, fruit protein, mustard protein, celery protein, sesame seed protein, nut proteins, such as cashew, pistachio, hazelnut, walnut, pecan, almond or Brazil nut protein, and animal proteins, such as fish protein, shellfish protein, egg protein, beef protein, pork protein, and milk protein. Allergens may also include polysaccharides, such as galactose-alpha-1 , 3-galactose (alpha-gal), pollen, such as grass, weed or tree pollen; animal dander; spores and mold.
  • plant proteins such as peanut protein, tree nut protein, soy protein, wheat protein, fruit protein, mustard protein, celery protein, sesame seed protein, nut proteins, such as cashew, pistachio, hazelnut, walnut, pecan, almond or Brazil nut protein
  • animal proteins such as fish protein, shellfish protein, egg protein, beef protein
  • the allergen may be comprised in an allergen extract, for example a dried powder, such as flour, freeze-dried milk, egg powder or animal protein powder.
  • a suitable powder may be generated from a natural source that contains the allergen.
  • a defatting or drying or desiccating step may be employed.
  • flour may be obtained by grinding raw nuts, grains or roots that contain the allergen, such as peanuts or tree nuts.
  • Dried powders, such as flours may be produced by conventional techniques or obtained from commercial suppliers.
  • a dried powder, such as a flour may for example comprise 25% to 60%, 30% to 55% or 35% to 45% allergen.
  • the amount of allergen extract in the allergen composition or formulation depends on the range of doses of allergen that are to be administered to a subject in the dosing regimen.
  • an allergen composition may comprise 1% (w/w) to 95% (w/w) allergen extract.
  • the allergen is peanut protein.
  • Peanut protein is the total protein content of a peanut and may contain multiple allergenic peanut proteins, for example one or more of Ara hi to h9.
  • peanut protein may comprise Ara h 1 , 2, 3 and 6.
  • Peanut protein may be extracted, isolated and/or purified from a peanut.
  • peanut protein may be provided as a peanut extract, such as peanut flour or peanut powder.
  • a peanut flour may for example comprise 35% to 55% peanut protein, for example 38% to 44% peanut protein.
  • Peanut flour is produced by crushing, grinding and/or milling whole peanuts. The flour may be partially or completely defatted to reduce the fat content. Defatting does not affect the allergenic peanut protein content of the flour.
  • the peanut protein content of peanut flour may be readily determined using standard techniques and is typically 50% (w/w) peanut protein. Peanut flour is widely available from commercial sources (e.g. Golden Peanut Company GA USA). Other peanut extracts which contain peanut protein may also be used in the methods described herein.
  • the immunotherapy methods described herein may further comprise an optional initial phase before the updosing phase.
  • the initial phase may comprise one or more administrations of the allergen at an initial dose.
  • the initial dose of allergen may be administered at regular time intervals, for example daily, every two, every three, every four, every five or every six days or weekly.
  • the initial dose is administered daily.
  • the initial dose is administered daily for 1 or more days before the up-dosing phase.
  • the initial dose is administered daily for 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13,14, 15, 16, 17, 18, 19, 20 or 21 days or longer.
  • the initial dose is administered daily for 14 days.
  • the initial dose is selected to cause little or no objective reaction in the patient.
  • a suitable initial dose may elicit an objective reaction in only 5% or less of the relevant allergic population.
  • the initial dose of allergen is 2 mg.
  • an initial dose of allergen may be 2mg of peanut protein.
  • the immunotherapy methods described herein comprise an up-dosing phase (step (a)) in which allergen is administered to the patient in a series of administrations in which the dose of allergen is increased incrementally with each administration from the initial dose to the maintenance dose.
  • the administrations of allergen may occur at regular time intervals of 1 day to 1 week.
  • the allergen may be administered daily, every two, every three, every four, every five or every six days or weekly.
  • the allergen is administered daily.
  • the maintenance dose of allergen is 200 mg.
  • a maintenance dose of allergen may be 200mg of peanut protein.
  • the dose of allergen administered to the patient is increased incrementally with each administration of allergen until it reaches the maintenance dose.
  • the dose of the allergen may be increased over the dose of the previous administration by an increment of between 1 to 10%, preferably 2 to 6%, starting with the initial dose and ending with the maintenance dose.
  • the dose may be increased by an increment of 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10% with each administration of allergen.
  • the increment of the increase in dose may be constant or fixed i.e. the % increase of each dose over the previous dose may be the same.
  • the dose of the allergen may be increased by an increment of 5% to 6% per administration from the initial dose to the maintenance dose.
  • the dose of allergen is increased by 5.7% per administration.
  • the dose of allergen may be increased by 5.7% per administration.
  • the up-dosing phase may last from 70 days to 1 year or longer, until the maintenance dose is reached.
  • the up-dosing phase may last from 3 to 6 months.
  • the up-dosing phase may last from 77 to 91 days, for example 84 days.
  • the patient may be periodically or continuously monitored for adverse reactions during the up-dosing phase.
  • the patient may be assessed and parameters such as pulse, blood pressure, peak expiratory flow rate in 1 second and oxygen saturation measured.
  • the patient may be monitored for the development of adverse allergic reactions or allergic symptoms, other side effects and/or changes in any of the measured parameters. Allergic symptoms may be treated with conventional medication as required. If an individual suffers a severe adverse reaction during the up-dosing phase, for example wheezing or other allergic symptoms assessed as serious by a clinician, then the individual may be subjected to a modified dose regimen or treatment of the individual may be paused or terminated, until the reason for the severe reaction has been identified and corrected.
  • the incremental increase in dose on each administration may be reduced or the allergen may be administered without an incremental increase, such that the same dose is administered consecutively for two or more administrations, or the allergen may be administered at a reduced dose.
  • smaller increments of increase in dose may be employed for a period of time.
  • the incremental increase in dose may be reduced by 50%.
  • the dose of the allergen may be increased by an increment of 2-3% per day, preferably by 2.85% per day.
  • the dose of the allergen may be increased by an increment of 2-3% per day, preferably by 2.85% per day.
  • the incrementally increasing daily dose may then be administered in the updosing phase for 154 days to 1 year or longer.
  • the up-dosing phase may last from 6 to 12 months.
  • the up-dosing phase may last from 161 to 175 days, for example, 168 days.
  • the allergen dose may be maintained over multiple consecutive administrations without any increase (i.e. the same dose may be administered two or more times); or the dose may be reduced, and the reduced dose maintained over multiple consecutive administrations without increase.
  • the dose of allergen that is administered to the patient is incrementally increased with each administration from an initial dose to a maintenance dose in the up-dosing phase.
  • the methods described herein comprise a maintenance phase, in which allergen is administered to the patient at the maintenance dose.
  • the administrations of allergen at the maintenance dose may occur at regular time intervals of 1 day to 1 week.
  • the allergen may be administered at the maintenance dose daily, every two, every three, every four, every five or every six days or weekly.
  • the allergen is administered daily at the maintenance dose.
  • the maintenance dose may be administered to the individual at regular time intervals in the maintenance phase for at least 3 months, at least 6 months, at least 1 year, at least 1 .5 years or at least 2 years.
  • the allergen is administered daily at the maintenance dose in the maintenance phase.
  • administration of the maintenance dose of allergen may be switched to a weekly regime.
  • the methods described herein may further comprise (c) administering the maintenance dose of the allergen weekly.
  • the maintenance dose may be administered to the individual weekly for at least 6 months, at least 1 year, at least 2 years, at least 2.5 years, at least 3 years or indefinitely.
  • the dose of allergen remains constant at the initial dose and the maintenance dose, respectively, over multiple administrations of the allergen.
  • These doses may be conveniently administered or dispensed in unit dose form i.e. the allergen is distributed into units, each of which contains a defined dose of the allergen. Suitable units are well-known in the art and include capsules.
  • the dose of each administration of the allergen is increased by a fixed increment over the dose of the previous administration.
  • the dose of allergen may be metered and/or measured for each administration. Conveniently, this may be performed by a dosing device which measures and dispenses the dose of allergen that is required for each administration in accordance with the dose regimen. Suitable devices are described below.
  • a dose of allergen may be increased from the previous dose by dispensing an increased amount or volume of the same allergen formulation as the previous dose or by dispensing the dose from a different allergen formulation with an increased concentration of allergen.
  • an allergen for use in a method of immunotherapy as described herein and the use of an allergen described herein in the manufacture of a medicament for use in a method of immunotherapy as described herein.
  • Allergen for use in methods described herein may be in a pharmaceutical composition or formulation, preferably a solid pharmaceutical composition or formulation.
  • Suitable pharmaceutical compositions or formulations may be stable and allow consistent and accurate dispensing of individual doses from a bulk composition or formulation.
  • a formulation or composition may comprise non-sterile free-flowing oral granules.
  • a pharmaceutical composition or formulation may comprise allergen or allergen extract as described above and one or more pharmaceutically acceptable excipients, such as carriers, fillers, binders, and lubricants.
  • a pharmaceutical composition or formulation may lack a glidant.
  • pharmaceutically acceptable relates to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound veterinary or medical judgement, suitable for use in contact with the tissues of a subject (e.g., human, or other mammal) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • Preferred excipients for use in the compositions described herein are not associated with hypersensitivity. Each carrier, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
  • Suitable carriers, excipients, etc. may be found in standard pharmaceutical texts, for example, Remington’s Pharmaceutical Sciences and The Handbook of Pharmaceutical Excipients, 4th edit., eds. R. C. Rowe et al, APhA Publications, 2003.
  • Allergen extracts such as peanut flour display poor flow characteristics, even when mixed with common excipients. This makes them incompatible with mechanical or automated dosing devices.
  • the allergen compositions described herein display good flow characteristics and are compatible with mechanical or automated dosing devices. These compositions are especially suitable for use in the methods described herein.
  • the amount of allergen in the allergen composition depends on the dosing regimen range that is to be employed. Typically, an allergen composition may comprise 0.3% to 50% (w/w) allergen.
  • a composition may be adapted to have good flow properties to enable accurate and precise dosing and avoid blockage within a device.
  • a composition may comprise granules of diluent and allergen. The size of the granules may be selected to provide a uniform composition at low doses (e.g. the initial dose), reduce or prevent the entrapment of granules within a device and/or reduce or prevent the segregation of the diluent and allergen granules with the composition. Granulation may also reduce the surface area of a composition compared with a powder, such as peanut flour. This may reduce the flavour of the allergen in the composition and thus promote patient compliance with the dosing regimen.
  • the particle size of the granules in an allergen composition described herein may be less than 750 pm, less than 500 pm or less than 355 pm. In some embodiments, the granules in an allergen composition described herein may be more than 250 pm. For example, the granules in an allergen composition described herein may be 250 to 500 pm.
  • Granule size may be determined by sieving in accordance with standard techniques (for example, ISO Standard 9276, ASTM C136). Compositions comprising granules of a target size may be produced by sieving to exclude larger or smaller granules.
  • a composition or formulation for use as described herein may comprise (i) granules comprising allergen extract, powdered mannitol and hypromellose, (ii) granules of mannitol and (iii) sodium stearyl fumarate.
  • a single allergen composition may be used to provide all of the doses of an allergen required for a method described herein.
  • two or more different allergen compositions may be used to provide the doses of an allergen required for a method described herein. This allows smaller amounts of allergen composition to be used to provide higher doses (e.g. the maintenance dose) and allows lower doses (e.g. the initial dose) to be measured and dispensed accurately.
  • a set of allergen compositions for use in the methods described herein.
  • the allergen compositions in the set may comprise different concentrations of allergen. All of the different doses of allergen required to up-dose a patient from the initial to the maintenance dose may be dispensed using different amounts of the allergen compositions in the set.
  • the set of allergen compositions consists of eight or fewer different compositions.
  • the set of allergen compositions consists of two different compositions.
  • the set may include a first composition comprising 1 to 10% (w/w) allergen, preferably 5% w/w allergen and a second composition comprising 15 to 30% (w/w) allergen, preferably 20% w/w allergen.
  • the different doses required for a method described herein may be generated by dispensing different amounts or quantities of the first and second compositions.
  • the allergen compositions in the set may comprise granules of allergen and granules of excipient.
  • the allergen compositions in the set may comprise granules comprising allergen extract, hypromellose and mannitol powder.
  • Suitable granules may for example comprise 25% (w/w) allergen extract, 3% hypromellose and 72% mannitol powder or 70% (w/w) allergen extract, 3% hypromellose and 27% mannitol powder.
  • the allergen granules may be formulated with sodium stearyl formulate and mannitol granules to produce the allergen compositions described herein.
  • the allergen compositions in the set may be produced using allergen extracts that vary in allergen content.
  • a first allergen composition with 5% allergen may comprise;
  • a first allergen composition may comprise 8 to 17% (w/w) allergen extract, 1 to 3% (w/w) hypromellose, 23 to 46% (w/w) mannitol powder, 33 to 66% (w/w) granular mannitol and 2% (w/w) sodium stearyl fumarate.
  • a second allergen composition with 20% allergen may comprise;
  • a second allergen composition with 20% (w/w) allergen may comprise 33 to 67 (w/w) allergen extract, 1 to 4% (w/w) hypromellose, 12 to 26% (w/w) mannitol powder, 2 to 51% (w/w) granular mannitol and 2% (w/w) sodium stearyl fumarate.
  • the allergen is peanut protein
  • the allergen extract is peanut flour
  • the allergen compositions in the set may be in unit dose form for the initial doses of the optional initial phase and the maintenance dose of step (b) and may be in bulk form for the incrementally increasing doses of the up-dosing phase of step (a).
  • allergens or allergen compositions described herein may be administered directly to a subject (i.e. without admixing with a foodstuff).
  • allergens or allergen compositions may be admixed with a foodstuff before administration.
  • an allergen composition may be admixed with a foodstuff and the foodstuff then ingested by the subject.
  • Suitable foodstuffs include dairy or dairy substitute products, such as yoghurt, milkshake or chocolate, or another food product with similar properties, cooked or baked food products, such as biscuits or cake; confectionery (e.g. chocolate, sweets and jellies) and beverages.
  • Dairy substitute products may include soy-based products.
  • the foodstuff may be semi-solid.
  • the method may comprise admixing allergen extract, mannitol powder, hypromellose and water, drying the admixture to produce granules and blending the granules with mannitol granules and sodium stearyl fumarate. Suitable proportions of these ingredients are provided above.
  • Suitable formulation processes that are well-known in the art. For example, as an initial step, the peanut protein content of a peanut flour or other peanut extract containing peanut protein may be determined. Suitable methods for characterising peanut protein content are well-known in the art and include RP-HLPC and LC-MS/MS.
  • the flour or other powder containing the peanut protein may be admixed with the mannitol powder in a granulator.
  • the mixture may then be admixed with an aqueous granulation solution comprising hypromellose and agitated, for example using an impeller, screws, or air, in a wet granulation process. Agitation of the mixture in the granulation solution in the presence of the hypromellose causes particles of the mixture to coalesce to produce wet granules.
  • the wet granules may then be dried, for example by heating to 50 to 70 °C, preferably about 65°C, to remove the aqueous granulation solution, leaving dry granules of peanut flour and mannitol bound together with hypromellose. Suitable wet granulation techniques are well-known in the art.
  • the granules may be blended with mannitol granules and sodium stearyl fumarate using standard blending techniques and sieved to generate the allergen composition.
  • the blend may be sieved using a 355 pm sieve to produce a composition comprising granules with a particle size of less than 355 pm.
  • the blend may be sieved using a 500 pm sieve and a 250 pm sieve, to produce a composition comprising granules with a particle size of 250-500 pm.
  • the allergen composition may be distributed into unit dose formulations for use in the initial and maintenance phases, for example by encapsulating into capsules or compressing into tablets, using standard techniques. Dose formulations may be tested using analytical techniques to confirm the purity and allergen content and subsequently packaged, for example in a blister pack.
  • the allergen composition may be in a bulk form for use in the up-dosing phase.
  • an allergen composition in bulk form may be packaged into a canister or cartridge for use in a dosing device.
  • the bulk form of the allergen composition may contain multiple doses of allergen and may form a reservoir from which aliquots of allergen of defined dose are dispensed.
  • the dosing device may dispense an amount of the allergen composition that contains a measured dose of allergen for administration in accordance with a method or dosage regimen described herein.
  • Doses of allergen in accordance with a dose regimen or method described herein may be metered and dispensed by a dosing device.
  • the device may provide an amount of allergen for administration having a dose that increases by a fixed increment over the dose of allergen of the previous administration.
  • a dosing device for use in a method of oral immunotherapy may comprise; a cartridge that contains an allergen composition for administration, an actuator for dispensing an amount of allergen composition from the cartridge that contains a defined dose of allergen, and a control unit comprising a processor, wherein the processor is programmed to operate the actuator to dispense amounts of allergen composition from the cartridge according to a pre-determined dose regimen.
  • the processor may be programmed to operate the actuator in accordance with an OIT method described herein.
  • the dosing device may further comprise a receptacle to contain the dispensed amount of allergen composition.
  • the receptacle may be detachable. For example, a detachable cup.
  • a dosing device described herein may comprise a cartridge containing an allergen composition for administration.
  • Each cartridge may be designed for insertion into the control unit, with the capacity to hold allergen compositions containing single or mixed allergens as per treatment requirements.
  • the allergen composition in the cartridge may be in bulk form and may form a reservoir of allergen from which portions may be dispensed by the actuator to provide defined doses of allergen.
  • the allergen composition in the cartridge may be non-sterile.
  • the allergen composition in the cartridge is preferably in a free-flowing solid form, such as powdered or granulated form.
  • the allergen composition is a composition as described above.
  • the allergen composition may be contained in a canister within the cartridge.
  • the cartridge may contain multiple canisters containing different allergen compositions.
  • cartridge may contain canisters containing a set of allergen compositions as described above.
  • the cartridge may comprise a first canister comprising a first allergen composition and a second canister comprising a second allergen composition.
  • Suitable cartridges may be replaceable and/or disposable after use.
  • a cartridge may further comprise a microchip containing information about allergen composition in the cartridge.
  • the information may include one or more of the permitted dose range for the cartridge, the concentration of allergen in the allergen composition, the current dose status (quantity of allergen composition remaining), and the expiry date of the allergen composition.
  • the actuator of the dosing device may dispense measured doses of allergen from the cartridge in accordance with a method described herein.
  • the allergen composition in the cartridge may have a defined allergen content (e.g. 5% (w/w) or 20% (w/w)).
  • the actuator of the dosing device may dispense a measured volume of the allergen composition that contains the dose defined by the predetermined dosing regimen. As the dose increases, the volume of allergen composition dispensed by the actuator may increase or the dosing device may dispense a different allergen composition with an increased allergen content.
  • Actuators suitable for dispensing allergen composition as known the art and include screw pumps, such as Archimedean screws and auger screws.
  • the actuator is operated by the control unit.
  • the control unit may be automated, semi-automated, or manually operated.
  • the control unit may comprise a processor.
  • the processor may be programmed or programmable with one or more dosing regimens. These may be stored in firmware on the device.
  • the processor may be programmed to dispense or provide doses of allergen in accordance with a method described herein or in accordance with step (ii) of a method described herein.
  • the processor may be programmed to dispense or provide doses of allergen from a set of allergen compositions describe herein.
  • the processor may be programmed to dispense or provide doses of allergen from a first allergen composition and a second allergen composition as described herein.
  • the processor may be programmed with a primary regimen. This may for example involve a daily dose increment of 5.7% from the previous day’s dose.
  • Alternate regimens may include half-speed up-dosing regimens, maintenance of the current dose, or reductions in the dose by half for a specified duration, all under physician guidance.
  • the processor may be programmed to adjust dosing increments based on feedback or physiological responses from the patient. Dosing adjustments may include real-time or delayed adjustments.
  • the processor may be programmed with dosing regimens directed to different allergens.
  • the device may comprise a display and the processor may be programmed to provide a graphical user interface on the display. This may allow the selection of different regimen options by the user.
  • the control unit may have data connectivity, such as wired and wireless data connections. Suitable connectivity may include Bluetooth and USB. This may for example allow the downloading of information to the processor or the uploading of information from the processor. This may allow remote monitoring and consultation with a physician and/or adjustment of the dosing regimen by a physician.
  • data connectivity such as wired and wireless data connections. Suitable connectivity may include Bluetooth and USB. This may for example allow the downloading of information to the processor or the uploading of information from the processor. This may allow remote monitoring and consultation with a physician and/or adjustment of the dosing regimen by a physician.
  • the processor may be programmed to notify users regarding drug administration timing for example using alarms, reminders, or other notification mechanisms. In some embodiments, the processor may be programmed to warn the user regarding unusual usage, such as administering doses more frequently, or at a different dose level, than normally expected. In some embodiments, the processor may be programmed to predict future side-effects of the treatment depending on the selected dosing regimen. The processor may be programmed to propose modifications to the dosing regimen based on these predictions of future side-effects. The prediction of future side-effects, or the proposal for a modification of the dosing regimen may be informed for example by automated statistical analysis, machine learning or artificial intelligence.
  • the control unit may also comprise sensor to detect levels of allergen composition in the cartridge.
  • the processor may be programmed to automatically track and notify users about the status of the allergens within the device, which may for example include alerts for expiry dates, depletion levels, or other relevant statuses.
  • Dosing devices for dispensing drugs or medicaments in solid form are known in the art (see for example EP3724099, EP4149406, EP3873398, EP4125774, and EP3986356) and may be suitable for use in dispensing defined doses of allergen from a bulk formulation as described herein,
  • the methods described herein may be used for any patient with allergy and are independent of the patient’s sensitivity or challenge threshold to allergen, the weight or height of the patient and other factors.
  • immunotherapy methods described herein may be useful in the treatment of peanut allergy.
  • the sensitivity of the patient to peanut protein may be reduced or abolished following treatment with peanut protein or allergen compositions comprising peanut protein as described herein.
  • An individual with peanut allergy may be allergic to any one or more of Ara hi to h9.
  • Individuals with peanut allergy from Western European populations are typically hypersensitive to one or more of Ara hi , h2 and h3 and most individuals display an allergic response to Ara h2.
  • other patterns of peanut allergen hypersensitivity may be more typical in individuals from other populations.
  • a patient with a peanut allergy may display peanut-specific serum IgE, i.e. IgE which specifically binds to peanut protein.
  • Patients may be diagnosed with peanut allergy according to standard clinical criteria.
  • an individual may tolerate or show no allergic reaction to the allergen at a dose corresponding to the maintenance dose. For example, an individual may show no allergic reaction to 200mg peanut protein following treatment as described herein. In some embodiments, an individual may show no allergic reaction to the allergen at a dose higher than the maintenance dose. For example, an individual may tolerate or show no allergic reaction to 600mg allergen, 10OOmg allergen or more than 1000mg allergen, following treatment as described herein.
  • Described herein is a Characterized Peanut Powder formulated in either multi-dose cartridges for a dose metering and dispensing device or in pull-apart capsules.
  • the cartridges require an electronic dosing device (see Figure 1) for dispensing medicinal substance prior to oral administration.
  • the cartridges and capsules have been developed for use as a peanut oral immunotherapy (OIT) for the treatment of patients aged 1 to 55 years with a confirmed diagnosis of peanut allergy.
  • OIT peanut oral immunotherapy
  • the dose metering and dispensing device ( Figure 1) was used during the up-dosing treatment phase, and the capsules were used for the maintenance doses.
  • the dose metering and dispensing device (OnDosis AB, Sweden), is a hand-held device designed to store, meter and dispense granules or pellets for oral use. It consists of 2 main components: a reusable electromechanical control unit, and a disposable drug-containing multi-dose cartridge with a detachable cup.
  • the control unit is drug-specific and is exclusively for use with the corresponding bespoke drug-filled cartridge.
  • the treatment program was peanut oral immunotherapy (OIT) for the mitigation or treatment of allergic reactions. It comprised an up-dosing phase and a maintenance phase. During the up-dosing phase, treatment was initiated using small, daily doses, which are gradually increased until a regular, daily maintenance dose can be tolerated. This was followed by maintenance treatment, which may last several years. Maintenance treatment began with daily dosing but may eventually be reduced from daily to weekly dosing.
  • OIT peanut oral immunotherapy
  • the medicinal substance was formulated as non-sterile free-flowing oral granules filled either into canisters within cartridges for product used in the up-dosing phase, or into pull-apart capsules for the maintenance phase.
  • the cartridge formulations were two active blend strengths (5% w/w and 20% w/w) with two corresponding placebo formulations using colour-matched placebo granules.
  • the cartridge was docked to the electromechanical hand-held control unit.
  • the cartridge and control unit together functioned as the novel dose metering and dispensing device which was designed to store, meter, and dispense precise and flexible doses.
  • the drug substance was lightly-roasted, partly-defatted powder of peanut.
  • the material was characterized before its use as a drug substance.
  • Peanut powder is well-established in the food industry. It contains Ara 1 , 2, 3 and 6, which are the main causative allergens for primary peanut allergy.
  • the electropherogram of Figure 2 shows example protein profiles of the drug substance, highlighting the individual allergens: As shown in Table 1 below, the drug substance was typically found to contain about 6.6% Ara h 1 , 3.7% Ara h 2, 11 .0% Ara h 3 and 1 .5% Ara h 6 relative to protein content.
  • the drug product was presented in cartridges containing a blend of one of two strengths: 5% w/w and 20% w/w peanut protein. Both comprised the unmodified drug substance (characterized peanut powder) formulated into free-flowing light brown to brown granules in white powder, pre-filled into multi-dose PC-ABS/PBT/PP cartridges to be docked into the control unit (device) for dispensing a specific dosage regimen as part of the up-dosing phase of treatment.
  • unmodified drug substance characterized peanut powder
  • PC-ABS/PBT/PP pre-filled into multi-dose PC-ABS/PBT/PP cartridges to be docked into the control unit (device) for dispensing a specific dosage regimen as part of the up-dosing phase of treatment.
  • composition of the drug product is listed in Table 2; Table 2: Composition of drug product (Cartridge)
  • Typical batch formulae for intermediate drug product granules are show in Table 4 and typical batch formulae for final product blends are shown in Table 5.
  • the steps involved in drug product manufacture are shown in Figure 3.
  • the drug product (cartridges) was manufactured in three stages: Granulation, Microchip flashing and Blending followed by cartridge filling and pouch packing.
  • Purified water was added to a beaker.
  • Peanut powder and granular mannitol were loaded into the granulation bowl of the fluid bed processor.
  • the granulation fluid was then sprayed into the fluidised bed.
  • the granules were then dried by a product temperature of 35°C for 45 minutes and 40°C for 10 minutes, and this cycle repeated as required, until the required moisture content was achieved.
  • the intermediate drug product granules produced during the granulation stage are stable and can be stored prior to the blending and cartridge filling and encapsulation stages.
  • Granules were blended with the diluent granular mannitol and the lubricant sodium stearyl fumarate, in quantities according to the batch formula, until a homogenous powder was achieved.
  • the blend was visually checked for homogeneity and filled into cartridges, depending on the dose concentration, using a manually operated cartridge filler.
  • the drug product was presented in two cartridge blend strengths: 5% w/w and 20% w/w. Both comprise the unmodified drug substance (characterised peanut powder) formulated into free-flowing light brown to brown granules in white powder, pre-filled into multi-dose PC-ABS/PBT/PP cartridges to be docked into the control unit (device) for dispensing a specific dosage regimen as part of the up-dosing phase of treatment that was then mixed with, room temperature, semi-solid, food.
  • unmodified drug substance characterised peanut powder
  • PC-ABS/PBT/PP pre-filled into multi-dose PC-ABS/PBT/PP cartridges to be docked into the control unit (device) for dispensing a specific dosage regimen as part of the up-dosing phase of treatment that was then mixed with, room temperature, semi-solid, food.
  • CA003 capsule formulation was comprised of a formulation of characterised peanut powder with hypromellose, trehalose, mannitol and stearic acid. The capsules were pulled apart and the contents mixed with, room temperature, semi-solid, food.
  • the hand-held Control Unit is an electromechanical device with a built-in rechargeable battery, embedded software (firmware) and a motor-driven mechanism to dispense precise doses of solid oral medication from within a pre-filled cartridge into a detachable Cup attached to the Cartridge ( Figure 1).
  • the Control Unit is configured to only function together with a correct and specific medication-containing Cartridge that is docked into the Control Unit by the user.
  • the Control Unit may be co-packaged with one or more Cartridges.
  • Dose adjustments and dispensing is controlled through buttons and a screen on the Control Unit.
  • a graphical user interface with symbols and numeric characters displays information about the dose strength, doses remaining, expiry date, battery level, and selected up-dosing regimen.
  • the Control Unit records and stores information about the Cartridge and the medicine it contains (including batch ID, expiry date, dose concentration, total and remaining doses) and an event log (including cartridge docking and undocking, regimen selection, timing and strength of dose taken) and information about the Control Unit (including expiry date and battery level).
  • the Control Unit is reusable and designed to be used for up to 24 months.
  • the Control Unit has a built-in Bluetooth Low Energy (BLE) antenna to enable connection to an optional, external software platform.
  • BLE Bluetooth Low Energy
  • the control unit includes the firmware (embedded software) that controls the system.
  • the firmware includes the graphical user interface to provide status information and regimen or dose selection by the patient, caregiver or physician, and a means of activating the dispensing function, if a compatible cartridge with the correct allergen composition is attached.
  • Oral immunotherapy regimens have been historically designed on the basis of regular fold-wise dose increases with periods of static dosing in between. Doses increase from a very low level to reach the maintenance dose level over a few months. For oral immunotherapy, these discrete updosing steps are relatively large, usually two-fold, with each followed by a series of days of dosing at home at the same dose level. In the case of CA003’s predecessor, CA002, each discrete dose level was taken for at least 14 days before the next updosing visit (discrete dose levels are 2, 5, 12.5, 25, 50, 100 and 200 mg peanut protein). These doses were selected based on the updosing protocol in STOP2, based on their good efficacy and safety profile. Because the discrete updosing steps represent several-fold increases in dose, they are associated with more adverse events than the days at the same dose and are thus required to be taken in a clinic under physician supervision.
  • STOP3E employs a continuous updosing regimen using a dosing device, starting at 2 mg peanut protein and increasing daily, in tiny steps (5.7%) to 200 mg peanut protein. This is instead of in the large, fold-wise dosing steps every 14 days, to reduce the frequency and severity of allergic reactions to a level where dosing can be safely carried out at home.
  • the dosing device is used only for the updosing part of treatment; patients would switch to capsules after reaching the maintenance phase (200 mg peanut protein).
  • a continuous updosing regimen that tracks the discrete regimen of CA002 is shown in Figure 6.
  • updosing starts with the first, 2 dose taken daily for 14 days. Thereafter, compared with CA002, the CA003 regimen is smoother and more conservative, instead of increasing suddenly to 5 mg peanut protein on day 15, the dose is increased by just 5.7% daily.
  • the 200 mg peanut protein maintenance dose is reached after a total of 98 days (14 weeks) of updosing (including the first 14 days at 2 mg peanut protein); an additional 14 days compared to CA002.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des méthodes d'immunothérapie comprenant l'administration d'allergènes, tels que la protéine d'arachide, à un individu en ayant besoin à des intervalles de temps réguliers. La dose d'allergène augmente de manière incrémentielle de 1 à 10 % à chaque administration d'une dose initiale à une dose de maintenance. La dose de maintenance de l'allergène est ensuite administrée à intervalles de temps réguliers. L'invention concerne également des compositions et des dispositifs de dosage destinés à être utilisés dans de telles méthodes.
PCT/EP2024/082996 2023-11-20 2024-11-20 Immunothérapie pour le traitement d'une allergie Pending WO2025109005A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB202317711 2023-11-20
GB2317711.6 2023-11-20

Publications (1)

Publication Number Publication Date
WO2025109005A1 true WO2025109005A1 (fr) 2025-05-30

Family

ID=93840678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/082996 Pending WO2025109005A1 (fr) 2023-11-20 2024-11-20 Immunothérapie pour le traitement d'une allergie

Country Status (1)

Country Link
WO (1) WO2025109005A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012123759A1 (fr) * 2011-03-17 2012-09-20 Cambridge Enterprise Limited Traitement pour l'allergie à l'arachide
US20200306184A1 (en) * 2017-11-06 2020-10-01 Cambridge Allergy Limited Allergenic protein formulations for immunotherapy
EP3724099A1 (fr) 2017-12-15 2020-10-21 Ondosis AB Dispositif d'administration pour comprimés de médicaments
EP3873398A1 (fr) 2018-11-02 2021-09-08 Ondosis AB Dispositif d'administration de médicaments sous forme de pastilles
EP3986356A2 (fr) 2019-06-19 2022-04-27 Ondosis AB Dispositif d'administration de médicaments en pastilles
EP4125774A1 (fr) 2020-04-01 2023-02-08 Ondosis AB Procédé de distribution de formes posologiques par voie orale
US20230049005A1 (en) * 2019-12-23 2023-02-16 Prota Therapeutics Pty Ltd Allergy treatment
EP4149406A1 (fr) 2020-05-15 2023-03-22 Ondosis AB Dispositif d'administration pour unités d'une forme posologique par voie orale

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012123759A1 (fr) * 2011-03-17 2012-09-20 Cambridge Enterprise Limited Traitement pour l'allergie à l'arachide
US20200306184A1 (en) * 2017-11-06 2020-10-01 Cambridge Allergy Limited Allergenic protein formulations for immunotherapy
EP3724099A1 (fr) 2017-12-15 2020-10-21 Ondosis AB Dispositif d'administration pour comprimés de médicaments
EP3873398A1 (fr) 2018-11-02 2021-09-08 Ondosis AB Dispositif d'administration de médicaments sous forme de pastilles
EP3986356A2 (fr) 2019-06-19 2022-04-27 Ondosis AB Dispositif d'administration de médicaments en pastilles
US20230049005A1 (en) * 2019-12-23 2023-02-16 Prota Therapeutics Pty Ltd Allergy treatment
EP4125774A1 (fr) 2020-04-01 2023-02-08 Ondosis AB Procédé de distribution de formes posologiques par voie orale
EP4149406A1 (fr) 2020-05-15 2023-03-22 Ondosis AB Dispositif d'administration pour unités d'une forme posologique par voie orale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. C. ROWE ET AL.: "Remington's Pharmaceutical Sciences and The Handbook of Pharmaceutical Excipients", 2003, APHA PUBLICATIONS

Similar Documents

Publication Publication Date Title
JP7012929B2 (ja) タマゴのタンパク質製剤およびその製造方法
US20160263212A1 (en) Compositions and methods for tolerizing the immune system to allergens
Ozalkaya et al. Effect of a galactagogue herbal tea on breast milk production and prolactin secretion by mothers of preterm babies
US20150343075A1 (en) Placebo formulations and uses thereof
BG99198A (en) Compositions with continuous release and method for their preparations
US20240252430A1 (en) Allergenic protein formulations for immunotherapy
WO2012047800A1 (fr) Procédés pour augmenter l'absorption de glucose par le muscle et réduire le temps de récupération du muscle employant un mélange d'acides aminés
JP5191955B2 (ja) 粘膜免疫調節剤並びにその用途
KR101487852B1 (ko) 신규조성물 및 그 용도
CN106727481B (zh) 绿原酸在制备增强食欲的药物或保健品中的用途
US20160279058A1 (en) Protein-based gel delivery system
GB2356346A (en) Food product for oral delivery of a pharmaceutical agent to a non-human animal comprising encapsulated particles of said agent distributed within the product
KR20090127260A (ko) 신경 안정제 및 기능성 식품
WO2025109005A1 (fr) Immunothérapie pour le traitement d'une allergie
CN101716180B (zh) 一种组合补充锌、钙药物及其制备方法
JP6018583B2 (ja) 植物エキス調合工程
US20240245084A1 (en) Medical food treatment for food allergies
JP5677937B2 (ja) 自律神経活動調節用組成物および自律神経を調節する方法
Konno Maitake SX-fraction: Possible hypoglycemic effect on diabetes mellitus
AU2009257513A1 (en) Fluid bed meal containing a marker and methods of making
RU2236859C2 (ru) Препарат "фитоомолаживающие"
RU2025984C1 (ru) Состав для приготовления жевательной резинки "здоровье-2"
US8524759B2 (en) Phenylbutazone carrier formulation showing increased bioactivity in animals
JP2008500371A (ja) 除染剤可食製品、その製造方法および使用
CN115177658B (zh) 一种用于降血糖的组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820266

Country of ref document: EP

Kind code of ref document: A1